Dianthus Therapeutics, Inc. /DE/
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.0M | $6.2M | $2.8M | — | — |
| Research and development | $145.6M | $83.1M | $32.8M | $29.4M | $46.8M |
| Operating expenses | $180.0M | $108.1M | $51.0M | $36.1M | $74.7M |
| Operating income | -$177.9M | -$101.9M | -$48.2M | -$29.7M | -$74.7M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$162.3M | -$85.0M | -$43.6M | -$28.5M | -$71.1M |
| Balance Sheet | |||||
| Cash and equivalents | $51.1M | $22.8M | $132.3M | $15.4M | $131.7M |
| Current assets | $409.4M | $280.9M | $177.5M | $82.0M | $180.7M |
| Total assets | $530.9M | $374.0M | $179.4M | $83.1M | $189.9M |
| Current liabilities | $30.7M | $18.5M | $9.6M | $8.2M | $10.9M |
| Total liabilities | $37.5M | $21.5M | $10.5M | $9.5M | $17.3M |
| Stockholders' equity | $493.4M | $352.5M | $168.9M | -$44.4M | -$17.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$129.1M | -$78.2M | -$36.9M | -$29.1M | -$59.5M |
| Depreciation and amortization | $111,000 | $96,000 | $67,000 | $1.9M | $2.0M |
| Stock-based compensation | $22.8M | $12.9M | $2.9M | $1.5M | $10.3M |
| Capital expenditure | — | — | — | $314,000 | $1.3M |
| Free cash flow | — | — | — | -$29.4M | -$60.8M |
| Impairments | — | — | — | $0 | $0 |
Shares outstanding 54.7M · Free float 66.9%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.